- 24 Downloads
An event is serious (based on the ICH definition) when the patient outcome is:
* congenital anomaly
* other medically important event
In a retrospective study of 61 patients, 12 patients (8 men and 4 women) aged 63−79 years were described, who developed anaemia, thrombocytopenia, anorexia, mucositis, malaise, hand-foot syndrome, hypertension, interstitial lung disease or febrile neutropenia during treatment with docetaxel and ramucirumab for non-small cell lung cancer (NSCLC) [durations of treatments to reactions onsets and outcomes not stated].
A 63-year-old man with pretreated NSCLC, started receiving IV docetaxel 60 mg/m2 plus IV ramucirumab 10 mg/kg on day 1 every 3 weeks. Subsequently, he developed grade 4 febrile neutropenia, which was considered as haematological toxicity following docetaxel and ramucirumab therapy.
A 75-year-old man with pretreated NSCLC, started receiving IV docetaxel 60 mg/m2plus...
- Hata A, et al. Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer. Oncotarget 9: 27789-27796, No. 45, 12 Jun 2018. Available from: URL: http://doi.org/10.18632/oncotarget.25578- Japan